CN1112367C - 包含食欲抑制肽的药物组合物的应用 - Google Patents

包含食欲抑制肽的药物组合物的应用 Download PDF

Info

Publication number
CN1112367C
CN1112367C CN97193525A CN97193525A CN1112367C CN 1112367 C CN1112367 C CN 1112367C CN 97193525 A CN97193525 A CN 97193525A CN 97193525 A CN97193525 A CN 97193525A CN 1112367 C CN1112367 C CN 1112367C
Authority
CN
China
Prior art keywords
arg
peptide
lys
pharmaceutical composition
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN97193525A
Other languages
English (en)
Chinese (zh)
Other versions
CN1215405A (zh
Inventor
L·提姆
B·S·乌尔弗
M·E·朱德格
O·D·马德森
J·J·霍尔斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1112367(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN1215405A publication Critical patent/CN1215405A/zh
Application granted granted Critical
Publication of CN1112367C publication Critical patent/CN1112367C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN97193525A 1996-03-01 1997-02-27 包含食欲抑制肽的药物组合物的应用 Expired - Lifetime CN1112367C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK0230/96 1996-03-01
DK0231/1996 1996-03-01
DK23096 1996-03-01
DK0230/1996 1996-03-01
DK0231/96 1996-03-01
DK23196 1996-03-01

Publications (2)

Publication Number Publication Date
CN1215405A CN1215405A (zh) 1999-04-28
CN1112367C true CN1112367C (zh) 2003-06-25

Family

ID=26063575

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97193525A Expired - Lifetime CN1112367C (zh) 1996-03-01 1997-02-27 包含食欲抑制肽的药物组合物的应用

Country Status (22)

Country Link
EP (4) EP2295453A3 (cg-RX-API-DMAC10.html)
JP (1) JP4064460B2 (cg-RX-API-DMAC10.html)
KR (1) KR100611130B1 (cg-RX-API-DMAC10.html)
CN (1) CN1112367C (cg-RX-API-DMAC10.html)
AT (3) ATE395359T1 (cg-RX-API-DMAC10.html)
AU (1) AU710818B2 (cg-RX-API-DMAC10.html)
BR (1) BR9707807A (cg-RX-API-DMAC10.html)
CA (1) CA2246733C (cg-RX-API-DMAC10.html)
CY (2) CY2619B2 (cg-RX-API-DMAC10.html)
CZ (1) CZ297338B6 (cg-RX-API-DMAC10.html)
DE (3) DE69738695D1 (cg-RX-API-DMAC10.html)
DK (2) DK0891378T3 (cg-RX-API-DMAC10.html)
ES (3) ES2306685T3 (cg-RX-API-DMAC10.html)
FR (1) FR13C0009I2 (cg-RX-API-DMAC10.html)
HU (1) HU229234B1 (cg-RX-API-DMAC10.html)
IL (1) IL125805A0 (cg-RX-API-DMAC10.html)
NO (2) NO323043B1 (cg-RX-API-DMAC10.html)
PL (1) PL187095B1 (cg-RX-API-DMAC10.html)
PT (1) PT1975177E (cg-RX-API-DMAC10.html)
RU (1) RU2197261C2 (cg-RX-API-DMAC10.html)
UA (1) UA70283C2 (cg-RX-API-DMAC10.html)
WO (1) WO1997031943A1 (cg-RX-API-DMAC10.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
HU229234B1 (en) * 1996-03-01 2013-09-30 Novo Nordisk As Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DK1231219T3 (da) 1996-04-12 2010-12-20 Ontario Inc 1149336 GLucagon-lignende peptid-2 analoger
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) * 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JP2001516765A (ja) * 1997-09-12 2001-10-02 ヴォルフ ゲオルグ フォースマン 真性糖尿病及び肥満の治療のための組成物
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
DE69942307D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
JP5161412B2 (ja) * 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP1592471B1 (en) 2003-02-04 2011-03-23 Novo Nordisk A/S Injection device with rotatable dose setting mechanism
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EA200601904A1 (ru) * 2004-04-15 2007-02-27 Алкермес, Инк. Система отсроченного высвобождения лекарственного средства на основе полимеров
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
PT1877435E (pt) 2005-05-04 2011-05-24 Zealand Pharma As An?logos de p?ptido-2 semelhante a glucagon
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
EP2051995B1 (en) 2006-11-08 2017-02-08 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
JP2010536717A (ja) * 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2844670B1 (en) 2012-05-03 2017-12-06 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP4424320A3 (en) 2016-12-09 2025-06-11 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
WO2018229252A1 (en) 2017-06-16 2018-12-20 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
EP3966224B1 (en) * 2019-05-06 2026-01-28 The University of Sydney Methods for the fractionation of proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
HU206897B (en) 1985-10-25 1993-01-28 Zymogenetics Inc Process for utilizing bar-1 gen for selecting strange proteins
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
WO1989001029A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Airlift insect cell culture
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
HU229234B1 (en) * 1996-03-01 2013-09-30 Novo Nordisk As Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Also Published As

Publication number Publication date
NO2013006I2 (cg-RX-API-DMAC10.html) 2013-03-12
HU229234B1 (en) 2013-09-30
BR9707807A (pt) 1999-07-27
KR100611130B1 (ko) 2006-11-30
FR13C0009I2 (fr) 2013-08-16
NO323043B1 (no) 2006-12-27
AU710818B2 (en) 1999-09-30
PL187095B1 (pl) 2004-05-31
ATE395359T1 (de) 2008-05-15
DE69740176D1 (de) 2011-05-26
HUP9902670A3 (en) 2000-02-28
UA70283C2 (en) 2004-10-15
CY2619B2 (cg-RX-API-DMAC10.html) 2013-03-13
NO984005L (no) 1998-08-31
ES2306685T3 (es) 2008-11-16
JP2000505460A (ja) 2000-05-09
PT1975177E (pt) 2011-07-26
DE69738695D1 (de) 2008-06-26
NO984005D0 (no) 1998-08-31
DK0891378T3 (da) 2003-01-06
EP2295453A2 (en) 2011-03-16
KR19990087439A (ko) 1999-12-27
EP1231218B1 (en) 2008-05-14
FR13C0009I1 (cg-RX-API-DMAC10.html) 2013-03-22
CA2246733C (en) 2010-07-20
EP2295453A3 (en) 2011-03-30
JP4064460B2 (ja) 2008-03-19
CY2013008I2 (el) 2015-08-05
CZ273698A3 (cs) 1998-12-16
DK1975177T3 (da) 2011-07-25
PL328732A1 (en) 1999-02-15
EP0891378B1 (en) 2002-11-13
IL125805A0 (en) 1999-04-11
CA2246733A1 (en) 1997-09-04
RU2197261C2 (ru) 2003-01-27
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
ES2364705T3 (es) 2011-09-12
ATE227737T1 (de) 2002-11-15
EP1975177A1 (en) 2008-10-01
CZ297338B6 (cs) 2006-11-15
EP0891378A1 (en) 1999-01-20
EP1975177B1 (en) 2011-04-13
EP1231218A2 (en) 2002-08-14
ES2187756T3 (es) 2003-06-16
NO2013006I1 (no) 2013-04-02
CN1215405A (zh) 1999-04-28
AU1871597A (en) 1997-09-16
CY2013008I1 (el) 2015-08-05
WO1997031943A1 (en) 1997-09-04
DE69717092D1 (de) 2002-12-19
DE69717092T2 (de) 2003-07-24

Similar Documents

Publication Publication Date Title
CN1112367C (zh) 包含食欲抑制肽的药物组合物的应用
US5912229A (en) Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP2440241B1 (en) Growth hormone polypeptides and methods of making and using same
US8030273B2 (en) Protracted exendin-4 compounds
US8703717B2 (en) Growth hormone polypeptides and methods of making and using same
US20070042956A1 (en) Novel GLP-1 compounds
KR20060109940A (ko) 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
US9849188B2 (en) Growth hormone polypeptides and methods of making and using same
EP3189072B1 (en) Gip peptide analogues
JP2002191385A (ja) 三つ葉状のペプチド２量体
KR20160007295A (ko) 인슐린 아날로그
HK1168776A (en) Growth hormone polypeptides and methods of making and using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20030625